Hospital Clinic of Barcelona: HIV Infections trials

The registry lists 16 HIV Infections studies with Hospital Clinic of Barcelona as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 2Phase 3 2Phase 4 6No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant RecipientsCompletedNCT02995824
• Validation Study of mHealth Technology in HIV to Improve Empowerment and Healthcare Utilisation: Research and Innovation to Generate Evidence for Personalised Care (EmERGE)Status unknownNCT02904733Not applicable
• Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-BCompletedNCT01923610Phase 1
• Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)CompletedNCT01576731Phase 4
• A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAARTCompletedNCT01571466Phase 1
• Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)CompletedNCT01533272Phase 4
• A New Telemedicine Approach for Chronic HIV/AIDS Patient Home CareCompletedNCT01117675Not applicable
• Integrase Resistance Analysis in HIV Patients Who Interrupted Raltegravir Due to Incomplete Viral SuppressionStatus unknownNCT00787774Not applicable
• Metabolic Effects of Enfuvirtide in Healthy VolunteersCompletedNCT00657761Phase 4
• Switching From PI to RALtegravir in HIV Stable PatientsCompletedNCT00528892Phase 3
• Dendritic Cell Vaccine in HIV-1 InfectionCompletedNCT00402142Phase 1/2
• Immune Reconstitution in naïve HIV Patients With CD4 <100 Cells/mL When Treated With Lopinavir or Efavirenz.TerminatedNCT00386659Phase 4
• Immunological and Viral Response to Antiretrovirals in HIV Patients With CD4 Cell Count Below 100CompletedNCT00385957Phase 4
• Atazanavir or Lopinavir in HIV Post-exposure ProphylaxisCompletedNCT00385645Phase 4
• Study of the Effectiveness of Passive Immunotherapy in HIV-Infected Patients Who Are in Virologic FailureSuspendedNCT00353327Phase 2/3
• Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral TherapyCompletedNCT00312832Not applicable